Picture of Oncolytics Biotech logo

ONCY — Oncolytics Biotech News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapSucker Stock

Brief: Oncolytics Biotech reports updated data from Phase 2 study of REOLYSIN

April 14 (Reuters) - Oncolytics Biotech Inc  ONC.TO  
    * Analysis showed a statistically significantly higher 
percentage of patients surviving two years in test arm versus 
control arm 
    * Says at time of data cut off, there were five survivors on 
study in test arm, and one survivor on study in crossover arm 
    * Two- and three-year survival for arms may continue to 
evolve 
 
Source text for Eikon:  ID:nCNWKdQkja  
Further company coverage:  ONC.TO  
 
 (Bengaluru Newsroom: +1-646-223-8780)

Recent news on Oncolytics Biotech

See all news